Patent · US Expired

Certain aryl substituted imidazopyrazinones; a new class of GABA brain receptor ligands

US5610299A · kind A · utility

4Cited by
2References
21Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 21, 1995
Grant dateMar 11, 1997
Priority date
Expiry dateDec 21, 2015

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07D487/04
  • WIPO fieldOrganic fine chemistry
  • WIPO sectorChemistry

Abstract

This invention encompasses compounds of formula I: ##STR1## or the pharmaceutically acceptable non-toxic salts thereof wherein: ##STR2## represents: ##STR3## where n is 0, 1, or 2; R.sub.1 and R.sub.2 are hydrogen or straight or branched chain alkyl groups; PA1 Y represents various organic and inorganic substituents; PA1 W represents an aromatic group substituted with various organic and inorganic substituents; PA1 A is CH or N; PA1 B is a substituted or unsubstituted carbon or N; and PA1 E is hydrogen or straight or branched alkyl groups. These compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs thereof and are useful in the diagnosis and treatment of anxiety, sleep, and seizure disorders, overdose with benzodiazepine type drugs, and enhancement of alertness.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.